Whatever happened to, “I like shiny things but I’d marry you with paper rings”? Well, Travis Kelce put a much fancier ring on the finger of Taylor Swift (see it here) and it wasn’t only an army of Swifties popping off on the news, but also the stocks of jewelers as traders bet that this big engagement will trigger a wave of fresh proposals.

President Donald Trump’s push to oust Federal Reserve Governor Lisa Cook from her position may have upset US bonds and the dollar, but it didn’t leave any mark on the stock market. The S&P 500 and Nasdaq 100 rose 0.4% while the Russell 2000 outperformed with a 0.8% advance on Tuesday.

Analysts are scrambling to increase their price targets for Nvidia ahead of its Q2 results, seemingly much more confident in the affirmation they’ll be getting on the longevity of the AI boom and Nvidia’s critical role in facilitating it. Usually they at least have the restraint until after Nvidia earnings blow them away. 

Already, those forgone sales have caused full-year revenues to be $10.5 billion lower than they otherwise would have, per Nvidia’s management, but it doesn’t seem like the company is benefiting vis-à-vis the Street’s view from this Chinese shift yet.

“We believe Nvidia earnings on deck is another positive catalyst for tech stocks that will further remind investors this is still only the bottom of the 2nd inning in the 9 inning game around building out the AI Revolution over the coming years to enterprises/consumers globally,” Wedbush Securities analyst Dan Ives wrote. “We continue to believe from our Asia field checks that demand to supply is 10:1 for Nvidia’s golden chips.”

The minimum investment is $501.

For years, they’ve been working on a real-world problem that still eludes Big Pharma. And now they may have one of the most exciting biologics in development.

They are the biotech disruptor, Cytonics. After successfully treating 10,000+ osteoarthritis patients with their first-generation OA therapy, Cytonics is pioneering a next-gen treatment: CYT-108. A genetically-engineered variant of the naturally-occurring Alpha-2-Macroglobulin protein, CYT-108 could become one of the first disease-modifying drugs for OA.

CYT-108 recently completed FDA Phase 1 clinical trials — but there’s more. Recent research suggests that CYT-108's "super A2M" activity may prove to be potent as a melanoma therapy. With a provisional U.S. patent filed to expand the drug into oncology, Cytonics is rapidly evolving into the next potential biotech breakthrough.